Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Crohn's Disease in Six Central Eastern European Countries

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.805
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Budget Impact Analysis of Biosimilar Infliximab (CT-P13) for the Treatment of Rheumatoid Arthritis in Six Central and Eastern European Countries

European Journal of Health Economics
Health PolicyEconomicsEconometricsFinance
2014English

PMD13 Assessing the Budget Impact of Using ScanBag® in CT in Six European Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

A Budget Impact Analysis of Adalimumab Biosimilar: The Italian Context

AboutOpen
2019English

Central and Eastern European Countries (Information)

The Journal of Political Theory, Political Philosophy and Sociology of Politics Politeia
2000English

Pcn69 - Budget Impact of Substituting Biosimilar Trastuzumab (Ct-P6) in Treating Gastric Cancer and Breast Cancer in 28 European Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php320 - Analysis of Hta Process on the Basis of Pharmacoeconomic Guidelines in Central Eastern European Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

New England Journal of Medicine
Medicine
2010English

Developing Cultural Industries in Central and Eastern European Countries

Management of Sustainable Development
2018English

Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

The Lancet
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy